AVXS-301
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 05, 2019
"Gene therapy update from Therapeutics in ALS session at #AANAM: Single administration of intrathecal AVXS-301 knocks down SOD1 in astrocytes, oligodentrocytes and motor neurons & nearly doubled the lifespan in SOD1 mice #EndALS @alsassociation @ALSA_MNNDSD"
(@Neuro_Edu_ET)
Preclinical
April 26, 2019
Intrathecal AAV9-SOD1-shRNA Administration for Amyotrophic Lateral Sclerosis
(AAN 2019)
- "Together, these results represent an important advancement towards clinical trials for ALS patients."
1 to 2
Of
2
Go to page
1